DZ3209A1 - Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine. - Google Patents

Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.

Info

Publication number: DZ3209A1
Authority: DZ; Algeria
Prior art keywords: migraine; treatment; receptor antagonists; antagonists used; iglur5 receptor
Prior art date: 1999-07-06

Application number

DZ003209A

Other languages

English (en)

French (fr)

Inventor

David Bleakman

Amy Suzon Chappell

Sandra Ann Filla

Kirk Willis Johnson

Paul Leslie Ornstein

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-06

Filing date

2000-06-27

Publication date

2001-01-11

2000-06-27 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-01-11 Application granted granted Critical

2001-01-11 Publication of DZ3209A1 publication Critical patent/DZ3209A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

DZ003209A 1999-07-06 2000-06-27 Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine. DZ3209A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14248599P	1999-07-06	1999-07-06
US15116599P	1999-08-27	1999-08-27
PCT/US2000/016297 WO2001001972A2 (en)	1999-07-06	2000-06-27	SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number	Publication Date
DZ3209A1 true DZ3209A1 (fr)	2001-01-11

Family

ID=26840135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ003209A DZ3209A1 (fr)	1999-07-06	2000-06-27	Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.

Country Status (28)

Country	Link
US (4)	US6566370B1 (zh)
EP (1)	EP1200073B1 (zh)
JP (1)	JP4619595B2 (zh)
KR (1)	KR20020024300A (zh)
CN (1)	CN1230174C (zh)
AR (1)	AR029373A1 (zh)
AU (1)	AU773304B2 (zh)
BR (1)	BR0012175A (zh)
CA (1)	CA2378613C (zh)
CZ (1)	CZ20014488A3 (zh)
DE (1)	DE60032905T2 (zh)
DK (1)	DK1200073T3 (zh)
DZ (1)	DZ3209A1 (zh)
EA (1)	EA004290B1 (zh)
ES (1)	ES2278619T3 (zh)
HK (1)	HK1047036A1 (zh)
HR (1)	HRP20020013A2 (zh)
HU (1)	HUP0202253A3 (zh)
IL (1)	IL146697A0 (zh)
MX (1)	MXPA01012726A (zh)
MY (1)	MY133503A (zh)
NO (1)	NO20016246L (zh)
NZ (1)	NZ515616A (zh)
PE (1)	PE20010299A1 (zh)
PT (1)	PT1200073E (zh)
SK (1)	SK112002A3 (zh)
TR (1)	TR200200066T2 (zh)
WO (1)	WO2001001972A2 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1257545A1 (en) *	1999-12-22	2002-11-20	Eli Lilly And Company	SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
JP2004520335A (ja) *	2001-01-05	2004-07-08	イーライ・リリー・アンド・カンパニー	興奮性アミノ酸レセプターアンタゴニスト
US6924294B2 (en)	2001-01-05	2005-08-02	Eli Lilly And Company	Excitatory amino acid receptor antagonists
EP1351952A2 (en) *	2001-01-05	2003-10-15	Eli Lilly And Company	Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US7205313B2 (en)	2001-01-05	2007-04-17	Eli Lilly And Company	Excitatory amino acid receptor antagonists
EP1351951A2 (en) *	2001-01-05	2003-10-15	Eli Lilly And Company	Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
DE60134427D1 (de) *	2001-01-05	2008-07-24	Lilly Co Eli	Exzitatorische aminosäure-rezeptor-antagonisten
WO2002053139A2 (en) *	2001-01-05	2002-07-11	Eli Lilly And Company	Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
GB0128996D0 (en)	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US20040082606A1 (en) *	2001-12-20	2004-04-29	Khau Vien Van	Excitatory amino acid receptor antagonists
SI1511741T1 (sl)	2002-04-26	2013-02-28	Eli Lilly And Company	Esterski derivativi dekahidroizokinolin-3-karboksilne kisline kot analgetiki
US7960436B2 (en)	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
RU2009110172A (ru)	2006-08-23	2010-09-27	Валеант Фармасьютикалс Интернэшнл (Us)	Производные 4-(n-азациклоалкил)анилидов в качестве модуляторов калиевых каналов
US8993593B2 (en)	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en)	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko)	2006-11-28	2009-08-03	밸리언트 파마슈티컬즈 인터내셔널	칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en)	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en)	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en)	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20200035035A (ko)	2017-07-31	2020-04-01	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
KR20240150533A (ko)	2018-03-05	2024-10-15	얀센 파마슈티카 엔브이	신경퇴행을 검출하기 위한 분석
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
CR20220250A (es)	2019-11-08	2022-08-19	Xenon Pharmaceuticals Inc	Métodos para el tratamiento de trastornos depresivos
CN116847843A (zh)	2021-02-09	2023-10-03	泽农医药公司	用于治疗快感缺乏的电压门控的钾通道开放剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5284957A (en)	1992-09-03	1994-02-08	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5356902A (en)	1992-11-06	1994-10-18	Eli Lilly And Company	Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en)	1994-05-31	1995-08-29	Eli Lilly And Company	Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) *	1994-11-18	1998-06-16	The General Hospital Corporation	Method for treating vascular headaches
CN1259126A (zh)	1997-04-07	2000-07-05	伊莱利利公司	药物
EP1208087B1 (en)	1999-07-06	2003-05-14	Eli Lilly And Company	Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

2000
- 2000-06-27 EP EP00944671A patent/EP1200073B1/en not_active Expired - Lifetime
- 2000-06-27 DZ DZ003209A patent/DZ3209A1/xx active
- 2000-06-27 DK DK00944671T patent/DK1200073T3/da active
- 2000-06-27 JP JP2001507466A patent/JP4619595B2/ja not_active Expired - Fee Related
- 2000-06-27 NZ NZ515616A patent/NZ515616A/en unknown
- 2000-06-27 BR BR0012175-4A patent/BR0012175A/pt not_active Application Discontinuation
- 2000-06-27 HR HR20020013A patent/HRP20020013A2/hr not_active Application Discontinuation
- 2000-06-27 EA EA200200132A patent/EA004290B1/ru not_active IP Right Cessation
- 2000-06-27 PT PT00944671T patent/PT1200073E/pt unknown
- 2000-06-27 IL IL14669700A patent/IL146697A0/xx unknown
- 2000-06-27 KR KR1020027000138A patent/KR20020024300A/ko not_active Withdrawn
- 2000-06-27 HU HU0202253A patent/HUP0202253A3/hu unknown
- 2000-06-27 SK SK11-2002A patent/SK112002A3/sk not_active Application Discontinuation
- 2000-06-27 US US10/009,655 patent/US6566370B1/en not_active Expired - Fee Related
- 2000-06-27 TR TR2002/00066T patent/TR200200066T2/xx unknown
- 2000-06-27 CN CNB008096880A patent/CN1230174C/zh not_active Expired - Fee Related
- 2000-06-27 MX MXPA01012726A patent/MXPA01012726A/es active IP Right Grant
- 2000-06-27 ES ES00944671T patent/ES2278619T3/es not_active Expired - Lifetime
- 2000-06-27 CZ CZ20014488A patent/CZ20014488A3/cs unknown
- 2000-06-27 HK HK02107174.1A patent/HK1047036A1/zh unknown
- 2000-06-27 CA CA002378613A patent/CA2378613C/en not_active Expired - Fee Related
- 2000-06-27 AU AU58732/00A patent/AU773304B2/en not_active Ceased
- 2000-06-27 DE DE60032905T patent/DE60032905T2/de not_active Expired - Lifetime
- 2000-06-27 WO PCT/US2000/016297 patent/WO2001001972A2/en not_active Ceased
- 2000-06-29 AR ARP000103296A patent/AR029373A1/es unknown
- 2000-07-04 PE PE2000000672A patent/PE20010299A1/es not_active Application Discontinuation
- 2000-07-04 MY MYPI20003046 patent/MY133503A/en unknown
2001
- 2001-12-19 NO NO20016246A patent/NO20016246L/no not_active Application Discontinuation
2003
- 2003-03-06 US US10/383,296 patent/US6759418B2/en not_active Expired - Fee Related
2004
- 2004-04-09 US US10/821,698 patent/US6855823B2/en not_active Expired - Fee Related
2005
- 2005-01-11 US US11/032,759 patent/US7157582B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2003503449A (ja)	2003-01-28
PT1200073E (pt)	2007-03-30
PE20010299A1 (es)	2001-03-07
US6566370B1 (en)	2003-05-20
US6855823B2 (en)	2005-02-15
WO2001001972A3 (en)	2001-12-06
NZ515616A (en)	2004-05-28
ES2278619T3 (es)	2007-08-16
BR0012175A (pt)	2002-03-05
HK1047036A1 (zh)	2003-02-07
NO20016246D0 (no)	2001-12-19
CA2378613C (en)	2007-10-02
CN1359289A (zh)	2002-07-17
HUP0202253A3 (en)	2003-12-29
EP1200073A2 (en)	2002-05-02
EA004290B1 (ru)	2004-02-26
WO2001001972A2 (en)	2001-01-11
SK112002A3 (en)	2003-05-02
KR20020024300A (ko)	2002-03-29
AU773304B2 (en)	2004-05-20
NO20016246L (no)	2002-03-04
JP4619595B2 (ja)	2011-01-26
US20040192722A1 (en)	2004-09-30
AU5873200A (en)	2001-01-22
DK1200073T3 (da)	2007-05-07
TR200200066T2 (tr)	2002-04-22
CN1230174C (zh)	2005-12-07
US20030199546A1 (en)	2003-10-23
EA200200132A1 (ru)	2002-06-27
EP1200073B1 (en)	2007-01-10
US6759418B2 (en)	2004-07-06
CA2378613A1 (en)	2001-01-11
DE60032905T2 (de)	2007-10-18
MXPA01012726A (es)	2002-07-02
CZ20014488A3 (cs)	2003-01-15
US7157582B2 (en)	2007-01-02
IL146697A0 (en)	2002-07-25
MY133503A (en)	2007-11-30
US20050159445A1 (en)	2005-07-21
HUP0202253A2 (hu)	2002-11-28
AR029373A1 (es)	2003-06-25
DE60032905D1 (de)	2007-02-22
HRP20020013A2 (en)	2003-08-31

Publication	Publication Date	Title
DZ3209A1 (fr)	2001-01-11	Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
ATE266655T1 (de)	2004-05-15	Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
MA26852A1 (fr)	2004-12-20	Agonistes selectifs du recepteur ep4 pour le traitement de l'osteoporose
EE200300246A (et)	2003-10-15	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
ATE318259T1 (de)	2006-03-15	Selektive neurokinin-antagonisten
DE60020327D1 (de)	2005-06-30	Wasserbehandlungsvorrichtung
NO20011025L (no)	2001-03-30	Selektiv behandling av endoteliale somatostatinreseptorer
EP1399160A4 (en)	2004-08-25	NR2B RECEPTOR ANTAGONISTS FOR TREATING OR PREVENTING MIGRAINE
DE60204951D1 (de)	2005-08-11	Ccr5 antagonisten verwendbar für die behandlung von aids
ATE304530T1 (de)	2005-09-15	Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ES1044084Y (es)	2000-08-16	Dispositivo para la limpieza de fondos de piscinas.
IS2196B (is)	2007-01-15	Blanda útskiptra bensimídasóla
MA25265A1 (fr)	2001-10-01	Antagoniste du recepteur de vitronectime.
ATE358483T1 (de)	2007-04-15	Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DK1180028T3 (da)	2007-05-21	IL-8-receptorantagonister
EP1309346A4 (en)	2005-06-01	TREATMENT OF HIV-1 INFECTION AND INFLAMMATORY DISEASES USING CYCLOPHILINE RECEPTOR ANTAGONISTS
FR2814367B1 (fr)	2008-12-26	Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
NO20020008L (no)	2002-02-27	Anvendelse av cortisol antagonister i behandling av hjertesvikt
DE60016769D1 (de)	2005-01-20	Antagonisten des vitronectin-receptors
NO20015774L (no)	2001-11-27	IL-8 reseptorantagonister
PT1448566E (pt)	2006-08-31	Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
MXPA03000500A (es)	2003-06-24	Uso de antagonistas del receptor de isoleucina 8 en el tratamiento de infecciones por virus.
ES1044076Y (es)	2000-08-16	Dispositivo para la limpieza de fondos de piscinas.
ITMI20031433A1 (it)	2005-01-12	Apparecchio e metodo di trattamento dell'acqua potabile per la preparazione di acqua per uso topico a scopo detergente, cosmetico e/o terapeutico
EP1372630A4 (en)	2005-03-23	MEANS FOR THE TREATMENT OF BLADDER HYPERACTIVITY